Trial · NCT02913924
Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients
NCT02913924, Phase 2, Completed, New York State Psychiatric Institute; results first posted 2021-08-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients. Trials, record NCT02913924. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02913924
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients
- NCT number
- NCT02913924
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 68 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Cannabis Use Disorder
- Interventions
- Clonazepam, Placebo
- First posted
- 2016-09-26
- Last updated
- 2021-08-06
- Results first posted
- 2021-08-06
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Cannabis Use Relapse | Number of days during 12 weeks of study participation | for inpatient participants the number of days till relapse to cannabis use, post inpatient discharge, as recorded on the time line follow-back and confirmed by urine toxicology. |
| Primary | Proportion of Cannabis Use Days Per Week | the 7 weeks of study participation or length of participants participation during the medication maintenance phase | for outpatient participants the proportion of cannabis use days per week as recorded by the Timeline Followback method |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time to Cannabis Use Relapse | Number of days during 12 weeks of study participation | 11 participants started the study utilizing the inpatient approach | days | MEDIAN |
| PRIMARY | Proportion of Cannabis Use Days Per Week | the 7 weeks of study participation or length of participants participation during the medication maintenance phase | proportion of use days | MEAN |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Cannabis Use Relapse | Clonazepam | 1 | Inter-Quartile Range 0 to 1 | days | |
| Time to Cannabis Use Relapse | Placebo | 1 | Inter-Quartile Range 0 to 39 | days | |
| Proportion of Cannabis Use Days Per Week | Clonazepam | week 1 | 0.74 | Standard Deviation 0.44 | proportion of use days |
| Proportion of Cannabis Use Days Per Week | Placebo | week 1 | 0.79 | Standard Deviation 0.41 | proportion of use days |
| Proportion of Cannabis Use Days Per Week | Clonazepam | week 2 | 0.78 | Standard Deviation 0.41 | proportion of use days |
| Proportion of Cannabis Use Days Per Week | Placebo | week 2 | 0.75 | Standard Deviation 0.44 | proportion of use days |
| Proportion of Cannabis Use Days Per Week | Clonazepam | week 3 | 0.71 | Standard Deviation 0.45 | proportion of use days |
| Proportion of Cannabis Use Days Per Week | Placebo | week 3 | 0.70 | Standard Deviation 0.46 | proportion of use days |
| Proportion of Cannabis Use Days Per Week | Clonazepam | week 4 | 0.67 | Standard Deviation 0.47 | proportion of use days |
| Proportion of Cannabis Use Days Per Week | Placebo | week 4 | 0.64 | Standard Deviation 0.48 | proportion of use days |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Clonazepam | 34 | |
| Overall Study | STARTED | Placebo | 34 | |
| Overall Study | COMPLETED | Clonazepam | 21 | |
| Overall Study | COMPLETED | Placebo | 21 | |
| Overall Study | NOT COMPLETED | Clonazepam | 13 | |
| Overall Study | NOT COMPLETED | Placebo | 13 |
Source ClinicalTrials.gov
Adverse events94
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | insomnia | General disorders | Clonazepam | 2 | 34 | 2 |
| other | insomnia | General disorders | Placebo | 5 | 34 | 5 |
| other | depression | Psychiatric disorders | Clonazepam | 2 | 34 | 2 |
| other | depression | Psychiatric disorders | Placebo | 3 | 34 | 3 |
| other | sedation | General disorders | Clonazepam | 10 | 34 | 10 |
| other | sedation | General disorders | Placebo | 0 | 34 | 0 |
| other | anxiety | Psychiatric disorders | Clonazepam | 1 | 34 | 1 |
| other | anxiety | Psychiatric disorders | Placebo | 3 | 34 | 3 |
| other | nausea | Gastrointestinal disorders | Clonazepam | 3 | 34 | 3 |
| other | nausea | Gastrointestinal disorders | Placebo | 2 | 34 | 2 |
1 to 10 of 94Source ClinicalTrials.gov
See all 94 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Clonazepam | 0 | 34 |
| Total, all-cause mortality | Placebo | 0 | 34 |
| Total, other adverse events | Clonazepam | 27 | 34 |
| Total, other adverse events | Placebo | 20 | 34 |
| Total, serious adverse events | Clonazepam | 1 | 34 |
| Total, serious adverse events | Placebo | 1 | 34 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U54DA037842 | Shared Pharmacotherapeutic Strategies for Cannabinoid & Opioid Use Disorders | LEVIN, FRANCES RUDNICK | NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC | NATIONAL INSTITUTE ON DRUG ABUSE | 2014 to 2018 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Clonazepam vs Placebo: deaths from any cause | Trial comparisons |
| Clonazepam vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02913924
GET https://conductscience.org/api/trials/v1/NCT02913924/events?page=2